> ## Documentation index
> Fetch the complete documentation index at: [llms.txt](../llms.txt)
> Use this file to discover all available pages before exploring further.

# Every source

The registries, regulators, journals, filings, and feeds Sleuth reads, grouped by what they answer.

[See the data page](https://www.sleuthinsights.com/data)

Sleuth collects every source below at the source and keeps it current. Each one feeds the records in the knowledge base. Use the filter to find a source by name or region.

### Clinical trials and registries

Who is running what study, where, and at what stage.

| Source | Region | What it covers |
| --- | --- | --- |
| **ClinicalTrials.gov** | Global | Trial registrations, status, arms, endpoints, sponsors, sites and posted results |
| **WHO ICTRP** | Global | Aggregated records from WHO primary registries worldwide |
| **EU Clinical Trials Register (EudraCT)** | EU | EU trials started before the Clinical Trials Regulation |
| **EU CTIS** | EU | EU trial applications, decisions and results under the Clinical Trials Regulation |
| **ISRCTN** | UK | UK primary registry |
| **DRKS** | EU | German Clinical Trials Register |
| **ChiCTR** | China | Chinese Clinical Trial Registry |
| **China Drug Trial Registration Platform (CDE)** | China | Mandatory registration for drug trials in China, often earlier and more complete than ChiCTR for industry trials |
| **ITMCTR** | China | International Traditional Medicine Clinical Trial Registry, via WHO ICTRP |
| **jRCT** | Japan | Japan Registry of Clinical Trials |
| **ANZCTR** | APAC | Australian New Zealand Clinical Trials Registry |
| **CTRI** | APAC | Clinical Trials Registry – India |
| **ReBEC** | LatAm | Brazilian Clinical Trials Registry, via WHO ICTRP |
| **CRIS** | Korea | Korea's Clinical Research Information Service, via WHO ICTRP |
| **IRCT** | Middle East and Africa | Iranian Registry of Clinical Trials, via WHO ICTRP |
| **PACTR** | Middle East and Africa | Pan African Clinical Trials Registry, via WHO ICTRP |
| **NL-OMON** | EU | Overview of Medical Research in the Netherlands, via WHO ICTRP |
| **RPCEC** | LatAm | Cuban Public Registry of Clinical Trials, via WHO ICTRP |
| **REPEC** | LatAm | Peruvian Clinical Trials Registry, via WHO ICTRP |
| **SLCTR** | APAC | Sri Lanka Clinical Trials Registry, via WHO ICTRP |
| **TCTR** | APAC | Thai Clinical Trials Registry, via WHO ICTRP |

### Scientific literature and preprints

What the published science says.

| Source | Region | What it covers |
| --- | --- | --- |
| **PubMed / MEDLINE** | Global | Biomedical citations and abstracts |
| **PubMed Central Open Access** | Global | Full-text open-access articles |
| **Select peer-reviewed clinical papers** | Global | Clinical trial publications beyond PubMed's open-access set |
| **Europe PMC** | EU | European full text, with links to grants |
| **bioRxiv** | Global | Biology preprints |
| **medRxiv** | Global | Clinical and health-science preprints |
| **Chinese-language journals, theses, and conference papers** | China | Chinese clinical and pharmacology research rarely indexed outside China |
| **Crossref** | Global | DOI metadata across journals, books and proceedings |
| **OpenAlex** | Global | Open index of papers, authors and institutions, used for KOL and lab mapping |

### Regulatory

What was approved, designated, delayed, or rejected, by which agency.

| Source | Region | What it covers |
| --- | --- | --- |
| **FDA drug labels (openFDA / SPL)** | US | Prescribing information, indications, boxed warnings |
| **DailyMed** | US | Current structured product labels from the National Library of Medicine |
| **Drugs@FDA** | US | Approval history, approval letters and review packages for NDAs and BLAs |
| **FDA approval and decision letters** | US | Approval letters and agency communications |
| **FDA Complete Response Letters** | US | Published CRLs explaining why applications were not approved |
| **FDA Advisory Committee materials** | US | Briefing documents, transcripts, minutes and votes |
| **Orange Book** | US | Approved small-molecule drugs with patents, exclusivities and therapeutic equivalence |
| **Purple Book** | US | Licensed biologics, biosimilars, interchangeables and reference product exclusivity |
| **CDER Novel Drug Approvals** | US | Annual lists of new molecular entities and new biologics |
| **CBER approved biologics and cell & gene therapies** | US | Vaccines, blood products, cellular and gene therapy approvals |
| **FDA Oncology approval notifications (OCE)** | US | Oncology and hematology approvals as they happen |
| **FDA press announcements** | US | Agency news releases |
| **Postmarketing Requirements and Commitments** | US | Required follow-on studies and their status |
| **REMS@FDA** | US | Risk evaluation and mitigation strategies |
| **FDA guidance documents** | US | Draft and final guidance on drug development and review |
| **Product-specific guidances** | US | Bioequivalence guidance for generics |
| **FDA notices in the Federal Register** | US | Approval withdrawals, advisory committee notices, exclusivity and user fee notices |
| **Orphan Drug Designations and Approvals database** | US | Every orphan designation with sponsor, date and indication |
| **Breakthrough Therapy designation lists (CDER, CBER)** | US | Breakthrough requests granted and resulting approvals |
| **Accelerated Approval lists** | US | Accelerated approvals, confirmatory trial status and withdrawals |
| **RMAT designations (CBER)** | US | Regenerative medicine advanced therapy designations |
| **Rare Pediatric Disease designations** | US | Designations eligible for priority review vouchers |
| **Priority review vouchers** | US | Vouchers granted, used and sold (rare pediatric, tropical disease, countermeasure) |
| **EMA CHMP opinions and meeting highlights** | EU | Monthly positive and negative opinions |
| **EMA European Public Assessment Reports (EPARs)** | EU | Full assessment reports for authorized medicines |
| **EC Union Register of medicinal products** | EU | EU marketing authorizations and decisions |
| **EU orphan designations (Community Register)** | EU | Orphan designations by sponsor and condition |
| **EMA PRIME** | EU | Medicines granted priority medicines support |
| **EMA Paediatric Investigation Plans** | EU | PIP decisions and waivers |
| **EMA withdrawn applications** | EU | Applications pulled before an opinion |
| **MHRA** | UK | UK approvals and product information |
| **NMPA** | China | Drug and biologic approvals and announcements |
| **CDE** | China | IND acceptances, priority review, breakthrough therapy and conditional approval lists; review reports |
| **PMDA** | Japan | Approvals list and review reports |
| **MHLW designations** | Japan | Sakigake, orphan and conditional approval designations |
| **Health Canada Drug Product Database** | Canada | Drugs marketed in Canada |
| **Health Canada Notice of Compliance database** | Canada | Canadian approvals, including conditional NOCs |
| **TGA Australian Register of Therapeutic Goods (ARTG)** | APAC | Australian registrations |
| **TGA Australian Public Assessment Reports (AusPARs)** | APAC | Public assessment reports for Australian approvals |
| **Project Orbis** | Global | FDA-led concurrent review of cancer drugs with partner agencies |
| **Access Consortium** | Global | Work-sharing reviews by the UK, Canada, Australia, Singapore, and Switzerland |

### Safety and pharmacovigilance

What safety signals exist after approval.

| Source | Region | What it covers |
| --- | --- | --- |
| **FAERS (via openFDA)** | US | Adverse event reports for drugs and therapeutic biologics |
| **FDA Drug Safety-related Labeling Changes (SrLC)** | US | Label safety updates by drug and date |
| **FDA Drug Safety Communications** | US | Agency safety notices by drug |
| **MedWatch safety alerts** | US | FDA safety alerts for drugs and biologics |
| **VAERS** | US | Vaccine adverse event reports |
| **EudraVigilance (adrreports.eu)** | EU | Suspected adverse reaction reports in the EU |
| **EMA PRAC signals and meeting highlights** | EU | Safety signals under EU review |
| **WHO VigiAccess** | Global | Public view of the WHO global safety database |

### Clinical guidelines and standard of care

How patients are treated today.

| Source | Region | What it covers |
| --- | --- | --- |
| **HHS HIV guidelines** | US | Treatment guidelines: HIV |
| **ACIP (CDC)** | US | Treatment guidelines: vaccines |
| **Clinical practice guidelines from major medical societies** | Global | Treatment guidelines across therapy areas |

### Epidemiology and public health

How many patients there are.

| Source | Region | What it covers |
| --- | --- | --- |
| **SEER** | US | US cancer incidence, prevalence and survival |
| **CDC WONDER** | US | US mortality and disease data |
| **NHANES (NCHS)** | US | US national health and nutrition survey: obesity, diabetes, hypertension, and more |
| **NHIS (NCHS)** | US | US national health interview survey |
| **Eurostat health database** | EU | EU health and causes-of-death data |
| **European Cancer Information System (ECIS)** | EU | EU cancer estimates by country |
| **China CDC** | China | Chinese disease surveillance and reports |
| **China National Cancer Center** | China | Annual Chinese cancer statistics |
| **WHO Global Health Observatory** | Global | Global health indicators |
| **OECD Health Statistics** | Global | Health and disease data for OECD countries |
| **Orphanet prevalence data** | Global | Rare disease prevalence and incidence |
| **UN World Population Prospects** | Global | Population by age and country |

### Pricing, reimbursement, and HTA

What a drug costs, and whether it gets paid for.

| Source | Region | What it covers |
| --- | --- | --- |
| **CMS ASP pricing files** | US | Medicare Part B average sales prices |
| **NADAC (Medicaid)** | US | National average pharmacy acquisition costs by drug |
| **Medicaid State Drug Utilization Data** | US | Medicaid prescriptions by drug and state |
| **Medicare Part D Spending Dashboard** | US | Medicare Part D spend and claims by drug |
| **Medicare Part B Spending Dashboard** | US | Medicare Part B spend and claims by drug |
| **Medicare Drug Price Negotiation** | US | Drugs selected under the Inflation Reduction Act and negotiated prices |
| **NICE technology appraisals** | UK | England reimbursement decisions |
| **G-BA (AMNOG)** | EU | German benefit decisions that set pricing |
| **IQWiG (AMNOG)** | EU | German benefit assessments behind G-BA decisions |
| **HAS Transparency Committee** | EU | French benefit ratings |
| **EU Joint Clinical Assessments** | EU | EU-wide HTA under the 2025 regulation |
| **China National Reimbursement Drug List (NHSA)** | China | NRDL listings and negotiated prices |
| **Japan NHI price listings** | Japan | Japanese reimbursement prices |

### Patents and IP

Who owns what, and when exclusivity ends.

| Source | Region | What it covers |
| --- | --- | --- |
| **US Patent and Trademark Office** | US | US patents and applications |
| **European Patent Office** | EU | European patents and applications |
| **Japan Patent Office** | Japan | Japanese patents and applications |
| **China National Intellectual Property Administration** | China | Chinese patents and applications |
| **WIPO PCT applications** | Global | International applications, often the first filing on a new program |
| **Orange Book patents and exclusivities** | US | Listed patents and exclusivity expiry per drug |
| **Paragraph IV certifications list** | US | Drugs facing generic patent challenges |
| **Purple Book patent lists** | US | Biologic patents disclosed in biosimilar litigation |

### Company filings and disclosures

What companies are required to disclose.

| Source | Region | What it covers |
| --- | --- | --- |
| **SEC EDGAR** | US | 10-K, 10-Q, 8-K, S-1, F-1, 20-F, 6-K and proxy filings |
| **SEC exhibits (license and collaboration agreements)** | US | Filed deal agreements with economics and terms |
| **SEC ownership filings (13D, 13G, 13F)** | US | Activist stakes and institutional holdings |
| **SEC Form D** | US | Private placements and venture rounds |
| **HKEXnews** | China | Hong Kong listings, including 18A biotech prospectuses and announcements |
| **CNInfo** | China | Shanghai and Shenzhen disclosures, including STAR Market biotechs |
| **EDINET** | Japan | Japanese securities filings |
| **TDnet** | Japan | Japanese timely disclosures |
| **DART** | Korea | Korean securities filings |

### Company websites and investor materials

What companies choose to say.

| Source | Region | What it covers |
| --- | --- | --- |
| **Company pipeline pages** | Global | Programs, targets, modalities and phases as companies list them, public and private |
| **Company press releases** | Global | Releases posted on company newsrooms |
| **Corporate and investor presentations** | Global | Pipeline decks and corporate overviews |
| **Earnings call transcripts** | Global | Management commentary and analyst Q&A |
| **Investor day and R&D day materials** | Global | Slides and transcripts from strategy events |
| **Healthcare investor conference presentations** | Global | Fireside chats and presentations at bank-hosted investor conferences and JPM week |
| **Corporate brochures and white papers** | Global | Company-issued technical and platform documents |
| **Posters and publications hosted on company sites** | Global | Scientific posters companies post after meetings |
| **Company-hosted KOL events** | Global | Webcasts with key opinion leaders |
| **Archived versions of company pages** | Global | Historical versions of pipeline pages, showing what was dropped or changed |
| **Public market data** | Global | Share prices and market caps for listed companies, from public web sources |

### News and newswires

What happened this week.

| Source | Region | What it covers |
| --- | --- | --- |
| **Business Wire** | Global | Company press releases |
| **PR Newswire** | Global | Company press releases |
| **GlobeNewswire** | Global | Company press releases |
| **Biotech and pharma trade press** | Global | Daily industry news on approvals, readouts, deals, and financings |

### Research funding and grants

What academic science is funded before it becomes a company.

| Source | Region | What it covers |
| --- | --- | --- |
| **NIH RePORTER** | US | NIH-funded projects, investigators and linked papers |
| **ARPA-H** | US | US advanced health research programs and awards |
| **SBIR / STTR awards** | US | US small business innovation grants to biotechs |
| **EU CORDIS** | EU | Horizon Europe and ERC projects |

### Biology and disease reference data

Public reference sets used alongside Sleuth's own ontology.

| Source | Region | What it covers |
| --- | --- | --- |
| **Disease Ontology** | Global | Disease classification |
| **MONDO** | Global | Unified disease ontology, strong on rare disease |
| **MeSH** | Global | NLM's controlled vocabulary used across PubMed |
| **ICD-10-CM** | US | US diagnosis codes |
| **ICD-11** | Global | WHO international diagnosis codes |
| **NCI Thesaurus** | US | Cancer terminology and drug names |
| **Orphanet nomenclature** | Global | Rare disease names, genes and classifications |
| **Open Targets** | Global | Target–disease evidence |
| **UniProt** | Global | Protein sequences and function |
| **HGNC** | Global | Official gene names |
| **NCBI Gene** | Global | Gene records |
| **Ensembl** | Global | Genome annotation |
| **Human Protein Atlas** | Global | Tissue and cell expression |
| **ChEMBL** | Global | Bioactive molecules and assay data |
| **IUPHAR/BPS Guide to Pharmacology** | Global | Targets and ligands |
| **PubChem** | Global | Chemical structures and bioactivity |
| **FDA Global Substance Registration System (UNII)** | US | Unique substance identifiers |
| **RxNorm** | US | Normalized US drug names |

### Social and alternative signals

Early signals outside formal disclosure.

| Source | Region | What it covers |
| --- | --- | --- |
| **WeChat official accounts** | China | Pipeline, financing and trial updates from Chinese biotechs, translated |
| **Company job postings** | Global | Hiring by function and site, an early read on program and commercial build-out |
| **People and executive moves** | Global | Leadership changes and team build-outs |
| **Social posts from companies, KOLs, and analysts** | Global | Real-time commentary around data releases and meetings |
| **Biotech podcasts and webinars** | Global | Executive and investor interviews, transcribed |

## Medical meetings

Abstracts, posters, oral presentation slides, and late-breakers from about 365 medical meetings across 20 therapy areas, with archives back to 2015, including China-focused meetings.

## Sell-side research

Research from 35+ banks and brokers. [Sell-side research](sell-side.md)

## Don't see a source you need?

Sleuth adds sources when customers need them. [Tell us which one](get-help.md)

## Related

- [What's in the knowledge base](knowledge-base.md): The records Sleuth works from, how many there are, and how they connect.
- [China coverage](china.md): How Sleuth covers Chinese programs, and how they show up next to everyone else's.
- [Sell-side research](sell-side.md): Research from 35+ banks and brokers, included in every plan, searchable next to everything else.

*Updated November 9, 2026.*
